DEXCOM INC Quarterly Deferred Income Tax Expense (Benefit) in USD from Q2 2017 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Dexcom Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q2 2017 to Q1 2024.
  • Dexcom Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$41.8M, a 349% decline year-over-year.
  • Dexcom Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$55M, a 155% decline from 2022.
  • Dexcom Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$21.6M, a 237% decline from 2021.
  • Dexcom Inc annual Deferred Income Tax Expense (Benefit) for 2021 was $15.8M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$41.8M -$32.5M -349% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q1 2023 -$9.3M -$9.4M -9400% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q1 2022 $100K +$400K Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-27
Q1 2021 -$300K -$300K Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q1 2020 $0 Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2017 $0 Oct 1, 2017 Dec 31, 2017 10-K 2019-02-21
Q3 2017 -$1.1M Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-01
Q2 2017 $17.1M Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.